Koninklijke DSM NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: MarketLine (a Datamonitor Company)
Koninklijke DSM NV to Sell DEXPlastomers V.o.F Joint Venture and LldPE Compact Solution Technology to Borealis AG
Koninklijke DSM NV (DSM) announced that it has reached an agreement with Borealis AG (Borealis) for the sale of DEXPlastomers V.o.F, a 50/50 Joint Venture of DSM with an affiliate of ExxonMobil Chemical. DSM will also sell its LldPE Compact Solution Technology to Borealis. Subject to customary approvals and notifications, the transaction is expected to close in Q1 2013. Established in 1996, DEXPlastomers is a 50/50 joint venture between DSM and Exxon Chemical Holland Ventures B.V., producing C8 plastomers and linear low density polyethylene. The Company's LldPE Compact Solution Technology was developed in the 1960's to produce polyethylenes in a certain density range and is instrumental to the operations of DEXPlastomers.
Latest Developments for Koninklijke DSM NV
- Koninklijke DSM NV and JLL Create Pharma Services Company In USD2.6 Billion Transaction; Global CDMO Company Combines DSM Pharmaceutical Products And Patheon Inc
- Koninklijke DSM NV Updates Its FY 2013 EBITDA Guidance Above Analysts' Estimates
- Koninklijke DSM NV Updates Its FY 2013-2015 EBITDA Guidance Below Analysts' Estimates
- Koninklijke DSM NV Confirms FY 2013 EBITDA Guidance
- Share this
- Digg this